Abstract
Global tuberculosis (TB) drug resistance (DR) surveillance is largely focused on rifampicin, leaving significant gaps in our understanding of resistance to other critical antibiotics. This study leverages public and surveillance M. tuberculosis (Mtb) whole genome sequencing (WGS) data to generate comprehensive country-level resistance prevalence estimates (antibiograms) for 12 drugs. By applying a validated random forest model and correcting for sampling biases—including outbreak clusters and resistance oversampling—we estimated resistance profiles for 29 countries. Our findings reveal high rates of fluoroquinolone resistance in South Asia and suggest that ethionamide remains a significantly underutilized drug for treating isoniazid-resistant TB.
Introduction
Current global TB surveillance is "rifampicin-centric." Because traditional culture-based drug susceptibility testing (DST) is slow and resource-intensive, international monitoring often relies on rifampicin resistance as a proxy for multi-drug resistance (MDR). This approach creates a "black box" regarding the effectiveness of other first- and second-line drugs. While Whole Genome Sequencing (WGS) offers a rapid alternative for resistance prediction, public genomic databases are inherently biased; researchers typically sequence isolates from major outbreaks or highly resistant cases rather than representative national samples. This study introduces a framework to de-bias public genomic data, providing the first global attempt at estimating comprehensive Mtb antibiograms.
Methods
To transform biased genomic data into reliable prevalence estimates, we developed a multi-step analytical pipeline:
- Genomic Prediction: We utilized a validated Random Forest (RF) classifier to predict phenotypic resistance based on mutations across 18 genetic loci.
- Outbreak Correction: To prevent localized outbreaks from skewing national data, we calculated pairwise Single Nucleotide Polymorphism (SNP) distances and pruned closely related isolates (distance ≤ 10 SNPs).
- Bayesian Bias Correction: We applied a Bayesian model to adjust for the imperfect sensitivity and specificity of the RF model, ensuring the estimates reflected true phenotypic resistance.
- Resistance Re-weighting: We used official WHO rifampicin resistance rates as a "ground truth" anchor. By re-weighting the oversampled MDR isolates in the genomic datasets, we normalized the data to reflect the actual national burden of each country.
Our primary dataset included 22,599 Mtb genomes curated from NCBI, PATRIC, and published literature. We validated these estimates using national drug resistance survey data from South Africa (2012–2014).
Key Results and Validation
The framework was applied to 29 countries that met the quality threshold of 100+ sequenced isolates. Validation against the South African national survey showed that marginal genotypic resistance estimates overlapped with survey results for nearly all drugs, though isoniazid and second-line injectables were slightly underestimated. Among MDR-TB cases, estimates for pyrazinamide and fluoroquinolones were highly accurate.
Globally, isoniazid mono-resistance was estimated at 10.9% (95% CI: 10.2-11.7%). Regional hotspots were prominent in former Soviet Union countries; for example, Russia was estimated to have a 66% isoniazid resistance rate.
Clinical and Policy Implications
The South Asia Fluoroquinolone Warning
One of the most critical findings concerns fluoroquinolone (FQ) resistance. In India and Pakistan, mono-levofloxacin resistance rates were estimated at 2.8% and 3.4%, respectively, among rifampicin-susceptible cases. This is particularly concerning as new, shorter 4-month treatment regimens rely heavily on FQs. If resistance is already present in supposedly "drug-susceptible" cases, these new regimens may face premature failure in high-burden regions.
Ethionamide Underutilization
The study revealed that 74.4% (IQR: 64.5-79.7%) of isoniazid-resistant isolates were predicted to be susceptible to ethionamide. Ethionamide is frequently sidelined in clinical practice due to its side-effect profile, but these results suggest it is a powerful, underused tool for treating isoniazid-resistant or MDR-TB.
Reality Check for Short-Course Regimens
The "Bangladesh regimen" for MDR-TB requires susceptibility to both pyrazinamide and levofloxacin. However, our global estimate found that only 15.1% (95% CI: 10.2-19.9%) of MDR-TB isolates were susceptible to both drugs. This suggests that the utility of such empiric short-course regimens may be more limited than previously hoped, necessitating more personalized treatment approaches.
Limitations
Despite the progress, geographic coverage remains a challenge; many high-burden countries are "genomic deserts" with insufficient data for reliable estimation. Furthermore, the current model cannot predict resistance to newer cornerstone MDR-TB drugs like bedaquiline or linezolid due to a lack of sufficient training data. Finally, the lack of clinical metadata in public databases (e.g., whether a patient is new or previously treated) remains a barrier to even more granular modeling.
Conclusion
This research demonstrates that public WGS data, when properly de-biased, can serve as a reliable proxy for expensive field surveys. By providing a more nuanced view of the TB resistance landscape, these genomic antibiograms can help clinicians and policymakers optimize treatment regimens and improve global TB control efforts. The results are accessible via an interactive web platform at GenTB.
Summary updated